Immune treatment with malaria cells for advanced solid cancers
Part of Cancer clinical trials.
This early-phase study tests a “malaria-based” immune treatment to help the immune system fight advanced cancers. It’s designed for people whose cancer can be measured on scans and whose organs and blood counts are strong enough for immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70 and can consent to the study
- You have advanced solid cancer that can be seen and measured on scans (not melanoma or certain other cancers)
- If you had chemotherapy or radiation before, you finished at least 3 months ago; if you had targeted drugs, enough time has passed based on that drug’s “half-life”
- Your heart tracing test (ECG) is normal or only mildly abnormal (ECG score 0 or 1), and your expected survival is at least 6 months
- Your blood counts and organ function are generally good (blood cell counts, kidney function, and liver function are within study limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests an immune-based treatment (using Plasmodium) for people with advanced breast cancer or advanced liver cancer. It aims to see whether the treatment is safe and whether it can help the body’s immune system fight the cancer.
This trial tests Plasmodium immunotherapy in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the treatment can slow tumor growth or improve cancer control.
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
This Phase 1/2 study tests an immune treatment made from Plasmodium (a malaria-related organism) in people with advanced solid cancers. It aims to see how well the treatment can control tumors and is primarily focused on early safety and whether it shows signs of benefit.
This trial tests a new immune cell therapy for people with advanced solid tumors of the lung, liver, colon, rectum, or breast. It aims to see if the treatment is safe and can help shrink or control the cancer.
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
Hear when a new Advanced Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.